出品I下海fallsea 胡不知 2025年11月的香港中环，长江集团中心49楼的会议室里，一场关乎亚洲零售巨头命运的讨论已持续数 周。当长江和记实业（00001.HK）高层最终敲定屈臣氏集团的上市方案时，窗外的维多利亚港正泛起 微光——这家拥有184年历史的零售标杆，将在2026年上半年踏上香港与英国双重上市的征程，计划募 资20亿美元的消息，很快通过财经媒体的版面传遍全球资本市场。 对李嘉诚家族而言，这绝非一次简单的资本运作。在长和系近年持续剥离非核心资产、聚焦基建与电讯 主业的背景下，将旗下最核心的零售资产推向资本市场，既是为集团现金流注入强心剂的"救赎之举"， 更是为屈臣氏开启独立发展通道的"野心布局"。从1841年广州的小药房起步，到如今全球拥有超1.6万 家门店的健康美妆零售巨头，屈臣氏的上市之路，映射着传统零售企业在消费变革与资本浪潮中的挣扎 与突围。 "这是长和系资本腾挪的关键一步，也是屈臣氏摆脱增长困境的必经之路。"香港资深投行人士陈锦兴在 接受虎嗅采访时直言，"20亿美元募资只是表面数字，背后是李氏家族对零售资产估值重构、区域战略 调整以及行业趋势判断的多重考量。" 长和系的"现金焦虑"： ...

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is transforming from a traditional Chinese medicine enterprise into a comprehensive health group by integrating medicine, health food, and medical services, leveraging its long history and technological innovation [1][7]. Group 1: Company Overview - Guangdong Wannianqing has over 130 years of history and has recently acquired upstream enterprises to enter the health food sector, creating a one-stop health management platform [1]. - The company has been recognized as a "Chinese Time-honored Brand" by the Ministry of Commerce in 2024, highlighting its craftsmanship and quality in the traditional Chinese medicine market [2]. - Currently, the company holds 101 drug approvals, including 32 original products and 38 products listed in the national medical insurance directory [2]. Group 2: Innovation and Technology - The company is focusing on modernizing traditional Chinese medicine through technological innovation, employing techniques such as vacuum low-temperature technology and ultra-fine pulverization to enhance production efficiency and product quality [4][5]. - A dual-driven model of "independent research and cooperative research" is being implemented to foster innovation in drug development, particularly in areas like gallbladder, diabetes, and cardiovascular diseases [5][6]. Group 3: Market Expansion and Ecosystem - Guangdong Wannianqing is building a comprehensive health ecosystem that integrates pharmaceutical manufacturing, healthcare, and health consumer products, aiming for a closed-loop system from cultivation to sales [7][8]. - The company has plans to develop health food products based on the "medicinal food homology" concept and is focusing on expanding its overseas market presence, particularly in Southeast Asia [8].

Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is transforming from a traditional Chinese medicine enterprise into a comprehensive health group by integrating medicine, health food, and medical services, leveraging its long history and technological innovation [1][4]. Group 1: Company Overview - Guangdong Wannianqing has over 130 years of history and has been recognized as a "Chinese Time-Honored Brand" by the Ministry of Commerce in 2024, marking its craftsmanship and quality in the traditional Chinese medicine market [1][2]. - The company currently holds 101 drug approvals, 32 original innovative products, and 38 products listed in the national medical insurance catalog, with key products including Shenshuijian Sugar-Lowering Tablets and Yixin Pills [1][2]. Group 2: Innovation and Technology - The company is implementing a "traditional craftsmanship + intelligent manufacturing" development model, focusing on modernizing production while preserving traditional techniques [3][4]. - Innovative technologies such as vacuum low-temperature belt technology and ultra-fine pulverization are being utilized to enhance the efficiency and quality of traditional Chinese medicine production [3][4]. Group 3: Research and Development - Guangdong Wannianqing employs a "dual-wheel drive" model for R&D, focusing on both independent and collaborative research, particularly in areas like gallbladder and cardiovascular drugs [4]. - The company collaborates with Shantou University to promote the rapid transformation of research results into practical applications, enhancing its core competitiveness [4]. Group 4: Market Expansion and Ecosystem - The company is building a comprehensive health ecosystem that integrates pharmaceutical manufacturing, healthcare, and health consumer products, aiming to transition into a comprehensive health group [5][6]. - Recent acquisitions, such as the 85% stake in Guangdong Tongren Pharmaceutical Co., Ltd., allow the company to better control the quality of medicinal materials and streamline the production process [5][6]. - The company is also expanding its health food business, focusing on high-end products like bird's nest and health teas, and plans to establish a "China Bird's Nest Port" in Shantou to enhance supply chain management [6].